Trial Profile
A PHASE 1, OPEN-LABEL, SINGLE-ARM STUDY IN HEALTHY SUBJECTS TO EVALUATE PAIN, TOLERABILITY, SAFETY, AND USABILITY OF A PREFILLED AUTOINJECTOR TO SELF-ADMINISTER ETROLIZUMAB SUBCUTANEOUSLY
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 05 Apr 2021
Price :
$35
*
At a glance
- Drugs Etrolizumab (Primary)
- Indications Crohn's disease
- Focus Adverse reactions; First in man
- Sponsors Genentech
- 29 Mar 2021 Results assessing toleratability of etrolizumab using an autoinjector in healthy volunteers, published in the Advances in Therapy
- 04 Aug 2016 Status changed from recruiting to completed.
- 15 Dec 2015 New trial record